Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Contrast-induced nephropathy (CIN) is a common and serious complication following procedures that use iodinated contrast media, leading to increased morbidity and mortality. Nicorandil, a potassium channel opener with vasodilatory effects, has been proposed as a potential nephroprotective agent. This systematic review and meta-analysis was conducted to determine the efficacy of nicorandil in preventing CIN in patients undergoing cardiovascular procedures involving contrast agents.
A systematic review and meta-analysis of randomized controlled trials (RCTs) was performed. We conducted a comprehensive search of PubMed, Embase, Cochrane Library, and Google Scholar for RCTs comparing nicorandil to placebo or standard hydration for CIN prevention. The primary outcome was the incidence of CIN. A fixed-effects model was used to calculate the pooled risk ratio (RR) and 95% confidence interval (CI), as statistical heterogeneity was low. Publication bias was assessed using a funnel plot.
Nine RCTs met the inclusion criteria, comprising a total of 2,276 patients (1,137 randomized to nicorandil and 1,139 to the control group). The pooled analysis showed that nicorandil administration was associated with a significant 65% reduction in the incidence of CIN compared to the control group (RR: 0.35, 95% CI: 0.28–0.44, p < 0.00001). No significant heterogeneity was observed across the included studies (I² = 0%). The funnel plot analysis was symmetrical, indicating a low likelihood of publication bias. Sensitivity analyses suggested that intravenous administration provided the most reliable estimates of efficacy.
This meta-analysis provides strong evidence that nicorandil is an effective intervention for reducing the risk of contrast-induced nephropathy. Given its significant protective effect and low heterogeneity across studies, nicorandil should be considered a valuable adjunct to standard prevention protocols, particularly for high-risk patients undergoing contrast-based procedures.
